Alluvi, formerly BI 4744, represents a notable breakthrough in weight control treatment. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/